Start:
May 2014
End:
December 2021
Enrollment:
90
Donepezil (brand name Aricept) is a medication commonly prescribed to treat Alzheimer's symptoms. This study will examine the sensitivity of functional magnetic resonance imaging (fMRI) to detect brain changes in healthy older adults at genetic risk for Alzheimer's disease who take donepezil. Participants with a family history of Alzheimer's will receive either 5 mg of donepezil for four weeks and 10 mg for 20 weeks or a placebo. Participants without a family history of Alzheimer's will undergo the study evaluations but will not receive the study drug. Researchers will measure the effects of donepezil on the brain using fMRI, a brain imaging method.
Minimum Age: 60 Years
Maximum Age: 75 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Lead: The Cleveland Clinic
Collaborator Sponsor
Source: ClinicalTrials.gov ID: NCT02087865
An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health